Neuron23
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined Parkinson's disease and immune-mediated disorders, anchored by the Phase 2 LRRK2 inhibitor NEU-411 and a proprietary machine-learning patient stratification platform.
- Company typePrivate
- Founded2018
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Neuron23 does
Neuron23 is a clinical-stage biotechnology company founded in late 2018 and headquartered in South San Francisco, California, that develops precision medicines for genetically defined neurodegenerative and immunological diseases. The pipeline is anchored by NEU-411, an oral, brain-penetrant, selective LRRK2 kinase inhibitor currently in the global Phase 2 NEULARK trial for early Parkinson's disease, with topline data anticipated in 2027. A second LRRK2 candidate, NEU-723, completed first-in-human Phase 1 dosing, while the company separately advances TYK2 inhibitors NEU-111 (Phase 1, oral allosteric inhibitor for immune-mediated inflammatory disorders) and NEU-627 (preclinical, brain-penetrant for multiple sclerosis).
The company's underlying technology is an integrated precision-medicine stack: a proprietary machine-learning patient selection model that identifies SNP signatures predictive of LRRK2 pathway overactivity in up to 30% of idiopathic PD patients; a first-of-its-kind next-generation sequencing companion diagnostic co-developed with QIAGEN and deployed exclusively at Quest Diagnostics; and a smartphone-based digital biomarker from Roche Information Solutions that serves as the primary endpoint in NEULARK. Neuron23 frames this as a disease-modifying approach that targets underlying drivers of PD progression rather than symptoms.
Neuron23 generates no product revenue today and operates a traditional biotech commercialization model. Capital is raised through successive venture rounds — over $310 million cumulatively across Series B, C, and D plus a $2.5 million Michael J. Fox Foundation grant — and the company has signaled that any approved therapy would likely be distributed through specialty pharmacies, healthcare providers, or partnership/licensing arrangements with larger pharmaceutical companies. Revenue mechanics through 2027 will be milestone- or royalty-based rather than product-based.
Neuron23 firmographics
Firmographics- Name
- Neuron23
- Legal name
- Neuron23 Inc.
- Website
- https://neuron23.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined Parkinson's disease and immune-mediated disorders, anchored by the Phase 2 LRRK2 inhibitor NEU-411 and a proprietary machine-learning patient stratification platform.
- Ownership category
- akta.pro rank
Neuron23 industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Neuron23 is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Neuron23 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical/Drug Development and Commercialization: As a clinical-stage biotechnology company, Neuron23's primary revenue model will be through the development and commercialization of novel therapeutics. The company is developing precision medicines for genetically defined neurological and immunological diseases, with lead programs NEU-411 (LRRK2 inhibitor for Parkinson's disease) and NEU-111 (TYK2 inhibitor for immune disorders). Successful commercialization would occur through direct sales, licensing agreements, or partnership with larger pharmaceutical companies.
- Companion Diagnostic Partnerships: Revenue may be generated through partnerships with diagnostic companies (QIAGEN, Quest Diagnostics) for companion diagnostic development and commercialization. These partnerships support clinical development and may include future royalty or revenue-sharing arrangements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Neuron23 product offering
Product offeringCore offering
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. Its pipeline comprises brain-penetrant LRRK2 inhibitors (lead asset NEU-411 in Phase 2 NEULARK for early Parkinson's disease, plus NEU-723) and TYK2 inhibitors (NEU-111 in Phase 1 for immune-mediated inflammatory disorders, plus preclinical NEU-627 for neuroinflammation). The drug programs are paired with a proprietary machine learning patient selection model and a first-in-class NGS companion diagnostic (developed with QIAGEN) that identifies patients with LRRK2-driven Parkinson's disease.
Product overview
Neuron23 is a clinical-stage biotechnology company developing a portfolio of precision medicines for genetically defined neurological and immunological diseases. The company's pipeline includes three clinical-stage programs: NEU-411 (Phase 2, LRRK2 inhibitor for Parkinson's disease), NEU-723 (Phase 1 completed, LRRK2 inhibitor for PD), and NEU-111 (Phase 1, TYK2 inhibitor for immune-mediated disorders). The pipeline is supported by a precision medicine platform that integrates machine learning-based patient selection algorithms, companion diagnostics developed with QIAGEN for genetic testing, and digital biomarker technology from Roche for disease monitoring. The company is also advancing NEU-627, a brain-penetrant TYK2 inhibitor for multiple sclerosis.
Differentiator
Problem solved
Functional benefit
Products and services
- NEU-411 A brain-penetrant, potent and selective oral inhibitor of LRRK2 kinase currently being evaluated in the global Phase 2 NEULARK clinical trial for early Parkinson's disease. Targets LRRK2-driven PD affecting up to 30% of people with idiopathic Parkinson's disease, offering a disease-modifying approach versus existing symptomatic-only treatments.
- NEU-723 A highly potent and selective brain-penetrant LRRK2 inhibitor that completed first-in-human Phase 1 clinical trial in healthy volunteers. Demonstrated strong disease-modifying potential with a higher therapeutic index than other LRRK2 candidates in development.
- NEU-111 A potent and highly selective oral allosteric inhibitor of TYK2 (tyrosine kinase 2) in Phase 1 clinical trials for immune-mediated inflammatory disorders. Reduces signaling through cytokine receptors including IL-12, IL-23 and interferon-alpha with potential applications in inflammatory bowel diseases, lupus, rheumatoid arthritis, and Type 1 diabetes.
- NEU-627 A brain-penetrant TYK2 inhibitor in preclinical development for multiple sclerosis and neuroinflammatory diseases, representing Neuron23's expansion into neuroinflammatory conditions.
- Precision Medicine Platform An integrated platform combining machine learning algorithms, human genetics, and biomarker discovery to identify genetic signatures predictive of therapeutic response. Utilizes companion diagnostics (developed with QIAGEN) and digital biomarkers (with Roche) to enable patient stratification and selection for targeted therapies.
Quantifiable outcome
- LRRK2 pathway engagement demonstrated with dramatic reductions in pS935-LRRK2 in blood and cerebrospinal fluid
- +3 more outcomes
Companies that use Neuron23
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Neuron23 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability2 records
Feature5 records
Neuron23 partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major, minor and core.
- Parkinson's FoundationmajorPD Trial Navigator program partnership. Foundation identified over 2,000 genetically eligible potential participants for NEULARK clinical trial by leveraging PD GENEration database of over 30,000 genetically tested Parkinson's patients combined with Neuron23's precision medicine tools.
- Tisch InstituteminorResearch collaboration for nonclinical studies on TYK2 inhibitors demonstrating impact in EAE model of multiple sclerosis and neuroinflammation. Studies conducted in collaboration with the Tisch Institute contributed to PNAS publication.
- Roche Information SolutionscoreCollaboration to incorporate digital biomarker developed by Roche as primary endpoint in Phase 2 NEULARK clinical trial. Roche provides device hardware, software, site support, and digital biomarker development expertise. Participants use smartphone equipped with proprietary software to measure PD symptoms.
- Sano GeneticscorePartnership to streamline patient referrals for NEULARK clinical trial. Sano offers saliva test kits that can identify people with LRRK2-driven PD and provides genetic counseling and engagement tools. Identified individuals referred to nearest NEULARK site.
- QIAGENcoreMaster Collaboration Agreement to develop companion diagnostic for LRRK2 inhibitor for Parkinson's disease. QIAGEN developing clinical trial assay using NGS workflow to detect biomarkers predictive of patient responsiveness. Quest Diagnostics deploying assay at laboratory in San Juan Capistrano, CA under exclusive agreement.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Neuron23 competitors and assessment
Company assessmentDirect peers
- Denali Therapeutics: Denali Therapeutics is the most directly comparable peer, developing a brain-penetrant LRRK2 inhibitor (BIIB122/DNL151) for Parkinson's disease in partnership with Biogen. Both companies target LRRK2-driven PD using a similar precision medicine framing and represent the leading edge of LRRK2 clinical development globally.
- Prothena: Prothena is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Parkinson's and Alzheimer's, sharing Neuron23's CNS drug development focus and clinical-stage biotech operating model.
- Annexon: Annexon is a clinical-stage biopharmaceutical company developing complement-mediated therapies for neurodegenerative diseases, sharing Neuron23's focus on targeted therapeutics for neurological conditions and clinical-stage development posture.
- Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company with Parkinson's disease programs (including tau-targeted and GBA1 approaches), mirroring Neuron23's targeted therapeutic strategy for genetically defined CNS disease subpopulations.
- Sage Therapeutics: Sage Therapeutics developed CNS-targeting therapeutics (Zulresso, Zurzuvae) with a similar focus on neurological and neuropsychiatric indications, mirroring Neuron23's CNS drug development profile; acquired by Biogen in 2024.
- Prevail Therapeutics: Prevail Therapeutics was a clinical-stage gene therapy company developing AAV-based therapies for neurodegenerative diseases including Parkinson's disease with GBA1 mutations, acquired by Eli Lilly in 2021 for ~$880M. It shares Neuron23's precision medicine approach to genetically defined PD subpopulations.
- Cerevel Therapeutics: Cerevel Therapeutics is a clinical-stage neuroscience company developing therapies for CNS disorders including Parkinson's disease, sharing Neuron23's CNS therapeutic focus, clinical-stage operating model, and similar investor sponsorship structure (including with Pfizer legacy program assets).
Broad incumbents
- Intra-Cellular Therapies: Intra-Cellular Therapies develops CNS therapeutics (CAPLYTA for schizophrenia and bipolar depression) with broader neuroscience focus, established regulatory and commercial infrastructure that parallels Neuron23's CNS disease focus at greater scale.
- Acadia Pharmaceuticals: Acadia Pharmaceuticals is an established biopharmaceutical company commercializing CNS therapies including treatments for Parkinson's disease psychosis (NUPLAZID), representing a commercially validated competitor/incumbent in the PD therapeutic market.
Others
- Biogen: Biogen is a large biopharmaceutical company with established CNS franchise (TYSABRI, SPINRAZA, ADUHELM) that partners with Denali on the leading LRRK2 inhibitor; represents the type of potential strategic acquirer/partner for Neuron23's NEU-411 program.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Neuron23 social profiles
Digital presenceNeuron23 financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neuron23 leadership team
Management profileNumber of profiles
Profiles15 records
Neuron23 funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neuron23 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neuron23
What does Neuron23 do?
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. Its pipeline comprises brain-penetrant LRRK2 inhibitors (lead asset NEU-411 in Phase 2 NEULARK for early Parkinson's disease, plus NEU-723) and TYK2 inhibitors (NEU-111 in Phase 1 for immune-mediated inflammatory disorders, plus preclinical NEU-627 for neuroinflammation). The drug programs are paired with a proprietary machine learning patient selection model and a first-in-class NGS companion diagnostic (developed with QIAGEN) that identifies patients with LRRK2-driven Parkinson's disease.
Is Neuron23 a public or private company?
Neuron23 is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neuron23 founded?
Neuron23 was founded in 2018. It employs 11 to 50 people.
Where is Neuron23 based?
Neuron23 is headquartered in San Francisco, United States, in the North America region.
How does Neuron23 make money?
Two revenue lines are on record. Pharmaceutical/Drug Development and Commercialization is the primary driver. The others are companion Diagnostic Partnerships.
Who are Neuron23's main competitors?
Direct peers on record are Denali Therapeutics, Prothena, Annexon, Voyager Therapeutics, Sage Therapeutics, Prevail Therapeutics and Cerevel Therapeutics. Broad incumbents are Intra-Cellular Therapies and Acadia Pharmaceuticals. Biogen is listed as an others.
Does Neuron23 have an API?
No public API is recorded for Neuron23.
What industry is Neuron23 in?
Neuron23's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.